RCP Therapeutics Ltd acquires the IP and assets of Telemolecular Corporation
New operational headquarters situated in London, UK
RCP Therapeutics, a biopharmaceuticals company specialising in converging nanotechnology and regenerative medical markets, announced that it has exclusively licensed technologies from Telemolecular Corporation (USA). The Company’s portfolio of intellectual property is strategically focused on the regenerative, preventative and curative elements of age related disease states.
RCP Therapeutics has identified a series of product candidates and has pilot launched its lead product candidate, Bimene, a novel cosmeceutical topical product, utilising its nano particle delivery platform acquired via licenses from universities and US based research institutions.
New management, appointed to run Telomolecular Corporation in May 2008, set in motion a business strategy culminating in the formation of RCP Therapeutics. Operationally, the Company will retain its research laboratory in Sacramento, securing the facilities status as RCP Therapeutics’ primary research and development site. Furthermore, the Company’s plans to expand the Californian operation and increase the number of scientists and staff employed at the site. Commercialisation of RCP Therapeutics’ cosmeceutical products in the US will be co-ordinated from the same location.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon
Aortic_valve
Category:Ophthalmic_equipment

Former unknowns: Noelin proteins central to learning ability of mammalian brains - German-American research team led by Freiburg physiologists reveals the fundamental importance of Noelin proteins for the plasticity of neurons
Patulous_Eustachian_tube
Evotec receives milestone payment as part of its discovery alliance with Boehringer Ingelheim
